Search alternatives:
point decrease » point increase (Expand Search)
non decrease » nn decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
12 nm » 10 nm (Expand Search), 12 mm (Expand Search), 12 m (Expand Search)
point decrease » point increase (Expand Search)
non decrease » nn decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
12 nm » 10 nm (Expand Search), 12 mm (Expand Search), 12 m (Expand Search)
-
98801
Proteome Analysis of Pod and Seed Development in the Model Legume <i>Lotus japonicus</i>
Published 2010“…Identified pod proteins represented enzymes from 85 different metabolic pathways, including storage globulins and a late embryogenesis abundant protein. In contrast to seed maturation, pod maturation was associated with decreasing total protein content, especially proteins involved in protein biosynthesis and photosynthesis. …”
-
98802
Image_1_Measurement of Ocular Compliance Using iPerfusion.pdf
Published 2019“…Measuring OC provides a powerful tool to assess corneoscleral biomechanics in mice and other species.…”
-
98803
Data_Sheet_1_Measurement of Ocular Compliance Using iPerfusion.pdf
Published 2019“…Measuring OC provides a powerful tool to assess corneoscleral biomechanics in mice and other species.…”
-
98804
-
98805
-
98806
-
98807
-
98808
-
98809
-
98810
-
98811
-
98812
-
98813
-
98814
-
98815
-
98816
-
98817
-
98818
-
98819
-
98820
Figure 2 from Targeting PRMT1 Reduces Cancer Persistence and Tumor Relapse in <i>EGFR</i>- and <i>KRAS</i>-Mutant Lung Cancer
Published 2025“…<b>A</b> and <b>B,</b> Cells were treated with type I PRMT inhibitors (PRMTi) at 0.1 or 1 μmol/L, with (<b>A</b>) or without (<b>B</b>) targeted drugs. …”